Table 2:
Best Overall Response by Cohort
| Best Overall Response (PRISSMM Criteria) | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| Cohort 1 (n 34) | Cohort 2 (n 48) | Cohort 3 (n 127) | ||||
|
| ||||||
| First CDK4/6i exposure | CDK4/6i retreatment | First CDK4/6i exposure | CDK4/6i retreatment | First CDK4/6i exposure | CDK4/6i retreatment | |
|
| ||||||
| Disease Progression | 0 | 5 (15%) | 14 (29.1%) | 23 (47.9%) | 39 (30.7%) | 52 (40.9%) |
|
| ||||||
| Stable Disease | 10 (29%) | 10 (29%) | 6 (12.5%) | 12 (25%) | 30 (23.6%) | 31 (24.4%) |
|
| ||||||
| Radiological Benefit | 11 (32%) | 10 (29%) | 25 (52.0%) | 7 (14.5%) | 54 (42.5%) | 28 (22.0%) |
|
| ||||||
| Non-evaluable (Treatment changed before first re-staging image) | 13 (38%) | 9 (26%) | 3 (6.2%) | 6 (12.5%) | 4 (3.1%) | 16 (12.6%) |
Best overall response by radiographic PRISSMM criteria is outlined by cohort in the table above. Patients that were nonevaluable were mainly patients that did not get radiographic imaging to determine disease state prior to changing therapies.